184 related articles for article (PubMed ID: 33068250)
1. Management of patients with chronic heart failure and type 2 diabetes mellitus: the SCODIAC-II study.
De Luca M; Bosso G; Valvano A; Guardasole V; Botta A; Carbone V; Carella G; Del Buono A; Di Giovanni G; Fimiani B; Guarnaccia F; Lapice E; Martedì E; Memoli G; Oliva D; Romano G; Cittadini A; Zito GB; Oliviero U
Intern Emerg Med; 2021 Jun; 16(4):895-903. PubMed ID: 33068250
[TBL] [Abstract][Full Text] [Related]
2. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
Rohde LE; Claggett BL; Wolsk E; Packer M; Zile M; Swedberg K; Rouleau J; Pfeffer MA; Desai AS; Lund LH; Kober L; Anand I; Merkely B; Senni M; Shi V; Rizkala A; Lefkowitz M; McMurray JJV; Solomon SD
Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551
[TBL] [Abstract][Full Text] [Related]
3. Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real-world data from the Swedish Heart Failure Registry.
Savarese G; Hage C; Benson L; Schrage B; Thorvaldsen T; Lundberg A; Fudim M; Linde C; Dahlström U; Rosano GMC; Lund LH
J Intern Med; 2021 Mar; 289(3):369-384. PubMed ID: 32776357
[TBL] [Abstract][Full Text] [Related]
4. Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex.
Mitchell GF; Solomon SD; Shah AM; Claggett BL; Fang JC; Izzo J; Abbas CA; Desai AS;
Circ Heart Fail; 2021 Mar; 14(3):e007891. PubMed ID: 33663237
[TBL] [Abstract][Full Text] [Related]
5. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study.
Jain AR; Aggarwal RK; Rao NS; Billa G; Kumar S
Indian Heart J; 2020; 72(6):535-540. PubMed ID: 33357641
[TBL] [Abstract][Full Text] [Related]
7. Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction.
Suzuki K; Claggett B; Minamisawa M; Nochioka K; Mitchell GF; Anand IS; Zannad F; Shah SJ; Lefkowitz M; Shi V; Pfeffer MA; McMurray JJV; Solomon SD
Hypertension; 2021 Feb; 77(2):546-556. PubMed ID: 33356401
[TBL] [Abstract][Full Text] [Related]
8. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
[TBL] [Abstract][Full Text] [Related]
9. Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF.
Selvaraj S; Claggett BL; Pfeffer MA; Desai AS; Mc Causland FR; McGrath MM; Anand IS; van Veldhuisen DJ; Kober L; Janssens S; Cleland JGF; Pieske B; Rouleau JL; Zile MR; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
Eur J Heart Fail; 2020 Nov; 22(11):2093-2101. PubMed ID: 32840930
[TBL] [Abstract][Full Text] [Related]
10. Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes.
Khan MS; Felker GM; Piña IL; Camacho A; Bapat D; Ibrahim NE; Maisel AS; Prescott MF; Ward JH; Solomon SD; Januzzi JL; Butler J
JACC Heart Fail; 2021 Feb; 9(2):137-145. PubMed ID: 33309581
[TBL] [Abstract][Full Text] [Related]
11. Sacubitril/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction.
Cosentino ER; Degli Esposti D; Miceli R; Bentivenga C; Landolfo M; Fg Cicero A; Berardi E; Spinardi L; Magri G; Dugato V; Borghi C
Curr Med Res Opin; 2019 Mar; 35(sup1):9-12. PubMed ID: 30864900
[TBL] [Abstract][Full Text] [Related]
12. Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
Tromp J; Claggett BL; Liu J; Jackson AM; Jhund PS; Køber L; Widimský J; Boytsov SA; Chopra VK; Anand IS; Ge J; Chen CH; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Rizkala AR; Inubushi-Molessa A; Lefkowitz MP; Shi VC; McMurray JJV; Solomon SD; Lam CSP;
Circ Heart Fail; 2021 Apr; 14(4):e007901. PubMed ID: 33866828
[TBL] [Abstract][Full Text] [Related]
13. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.
Senni M; Paulus WJ; Gavazzi A; Fraser AG; Díez J; Solomon SD; Smiseth OA; Guazzi M; Lam CS; Maggioni AP; Tschöpe C; Metra M; Hummel SL; Edelmann F; Ambrosio G; Stewart Coats AJ; Filippatos GS; Gheorghiade M; Anker SD; Levy D; Pfeffer MA; Stough WG; Pieske BM
Eur Heart J; 2014 Oct; 35(40):2797-815. PubMed ID: 25104786
[TBL] [Abstract][Full Text] [Related]
14. Impact of sacubitril/valsartan treatment on depression and anxiety in heart failure with reduced ejection fraction.
Dereli S; Kılınçel O; Çerik İB; Kaya A
Acta Cardiol; 2020 Dec; 75(8):774-782. PubMed ID: 32186467
[No Abstract] [Full Text] [Related]
15. Impact of Sacubitril/Valsartan on Right Heart Failure.
Imamura T; Hori M; Ueno H; Kinugawa K
Int Heart J; 2021 Jul; 62(4):932-934. PubMed ID: 34276024
[TBL] [Abstract][Full Text] [Related]
16. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study.
Zile MR; Jhund PS; Baicu CF; Claggett BL; Pieske B; Voors AA; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD;
Circ Heart Fail; 2016 Jan; 9(1):. PubMed ID: 26754625
[TBL] [Abstract][Full Text] [Related]
17. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
18. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
[TBL] [Abstract][Full Text] [Related]
19. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.
Seferovic JP; Claggett B; Seidelmann SB; Seely EW; Packer M; Zile MR; Rouleau JL; Swedberg K; Lefkowitz M; Shi VC; Desai AS; McMurray JJV; Solomon SD
Lancet Diabetes Endocrinol; 2017 May; 5(5):333-340. PubMed ID: 28330649
[TBL] [Abstract][Full Text] [Related]
20. "Real World" Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry.
Simpson J; Benson L; Jhund PS; Dahlström U; McMurray JJV; Lund LH
Cardiovasc Drugs Ther; 2019 Jun; 33(3):315-322. PubMed ID: 30903545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]